×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
TARA – protara therapeutics, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
TARA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/12
07:00 am
tara
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
Medium
Report
Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones
1/9
06:10 am
tara
Protara Therapeutics (NASDAQ:TARA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
Low
Report
Protara Therapeutics (NASDAQ:TARA) was upgraded by analysts at Piper Sandler to a "strong-buy" rating.
1/7
08:10 am
tara
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support [Yahoo! Finance]
Medium
Report
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support [Yahoo! Finance]
1/7
08:00 am
tara
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
1/7
08:00 am
tara
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
Medium
Report
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support
1/7
06:05 am
tara
Protara Therapeutics (NASDAQ:TARA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
Medium
Report
Protara Therapeutics (NASDAQ:TARA) is now covered by analysts at Piper Sandler. They set an "overweight" rating on the stock.
1/5
08:06 am
tara
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations [Yahoo! Finance]
Medium
Report
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations [Yahoo! Finance]
1/5
08:00 am
tara
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
Medium
Report
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations
Date
Time
Symbol
Company Name
Action
%Chg
11/10/2025
08:00 am
tara
protara therapeutics, inc.
BEAT
Report
8.9%
protara therapeutics, inc.
8/11/2025
08:00 am
tara
protara therapeutics, inc.
BEAT
Report
-1.0%
protara therapeutics, inc.
5/8/2025
08:00 am
tara
protara therapeutics, inc.
BEAT
Report
0.9%
protara therapeutics, inc.
Date
Time
Symbol
Headline
Impact
12/15
04:15 pm
tara
Form 8-K Protara Therapeutics, For: Dec 15
Low
Report
Form 8-K Protara Therapeutics, For: Dec 15
12/9
04:16 pm
tara
Form 424B7 Protara Therapeutics,
Low
Report
Form 424B7 Protara Therapeutics,
12/8
04:15 pm
tara
Form 8-K Protara Therapeutics, For: Dec 04
Low
Report
Form 8-K Protara Therapeutics, For: Dec 04
12/5
04:29 pm
tara
Form 424B5 Protara Therapeutics,
Low
Report
Form 424B5 Protara Therapeutics,
12/4
04:29 pm
tara
Form 424B5 Protara Therapeutics,
Medium
Report
Form 424B5 Protara Therapeutics,
12/3
08:09 am
tara
Form 8-K Protara Therapeutics, For: Dec 03
Medium
Report
Form 8-K Protara Therapeutics, For: Dec 03
11/19
09:16 am
tara
Form 8-K Protara Therapeutics, For: Nov 19
Medium
Report
Form 8-K Protara Therapeutics, For: Nov 19
11/14
11:58 am
tara
Form SCHEDULE 13G/A Protara Therapeutics, Filed by: JANUS HENDERSON GROUP PLC
Low
Report
Form SCHEDULE 13G/A Protara Therapeutics, Filed by: JANUS HENDERSON GROUP PLC
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/23
Form 8-K ArTara Therapeutics, For: Mar 18
14.2%
1/21 Form SC 13D ArTara Therapeutics, Filed by: Opaleye Management Inc. 12.8%
2/4 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.9%
3/30 Form 8-K ArTara Therapeutics, For: Mar 26 6.5%
4/21 Verona Pharma plc (NASDAQ: TARA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
2/11 Form 424B3 ArTara Therapeutics, 4.6%
4/2 ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 4.3%
1/15 Form S-8 ArTara Therapeutics, 3.7%
2/14 Form SC 13G/A ArTara Therapeutics, Filed by: INTERSOUTH PARTNERS VI LP 2.7%
4/23 Form DEF 14A ArTara Therapeutics, For: Jun 09 2.5%
1/21 Form SC 13D ArTara Therapeutics, Filed by: Opaleye Management Inc. 12.8%
2/4 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. 6.9%
3/30 Form 8-K ArTara Therapeutics, For: Mar 26 6.5%
4/21 Verona Pharma plc (NASDAQ: TARA) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 5.7%
2/11 Form 424B3 ArTara Therapeutics, 4.6%
4/2 ArTara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 4.3%
1/15 Form S-8 ArTara Therapeutics, 3.7%
2/14 Form SC 13G/A ArTara Therapeutics, Filed by: INTERSOUTH PARTNERS VI LP 2.7%
4/23 Form DEF 14A ArTara Therapeutics, For: Jun 09 2.5%
TOP News Decliners
2/21
Form SC 13G ArTara Therapeutics, Filed by: Ikarian Capital, LLC
-7.6%
4/9 Form SEC STAFF LETTER ArTara Therapeutics, -6.1%
3/20 Form 10-K ArTara Therapeutics, For: Dec 31 -4.6%
4/18 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. -4.5%
1/30 Form S-3 ArTara Therapeutics, -4.0%
1/13 Form 3 ArTara Therapeutics, For: Jan 09 Filed by: Opaleye, L.P. -3.6%
2/18 Form 4/A ArTara Therapeutics, For: Jan 09 Filed by: Shefferman Jesse -3.1%
1/27 Form SC 13D/A ArTara Therapeutics, Filed by: Opaleye Management Inc. -1.6%
1/16 Form SC 13G ArTara Therapeutics, Filed by: Wilson Donald R. Jr. -0.6%
4/9 Form SEC STAFF LETTER ArTara Therapeutics, -6.1%
3/20 Form 10-K ArTara Therapeutics, For: Dec 31 -4.6%
4/18 Verona Pharma plc (NASDAQ: TARA) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $27.00 price target on the stock. -4.5%
1/30 Form S-3 ArTara Therapeutics, -4.0%
1/13 Form 3 ArTara Therapeutics, For: Jan 09 Filed by: Opaleye, L.P. -3.6%
2/18 Form 4/A ArTara Therapeutics, For: Jan 09 Filed by: Shefferman Jesse -3.1%
1/27 Form SC 13D/A ArTara Therapeutics, Filed by: Opaleye Management Inc. -1.6%
1/16 Form SC 13G ArTara Therapeutics, Filed by: Wilson Donald R. Jr. -0.6%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: